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Background
Swertiamarin, a secoiridoid glycoside is found in abundant
quantity in Enicostemma Littorale herb and is the main
constituent responsible for anti-diabetic and anti-obesity
effects of the plant extract. It has been reported to act on
various enzymes and transcription factors involved in
glucose and lipid metabolism, including inhibition of the
enzyme HMG-CoA reductase which might be one of the
mechanisms responsible for the antihyperlipidaemic activ-
ity. However, owing to its high water solubility, it has a
low plasma half life; and thus we have designed its deriva-
tives which bind more efficiently with HMG CoA
Reductase.
Materials and methods
Docking was carried out using software namely Autodock
and Vina, and repeated at least thrice to minimise the
error and to confirm the repeatability. The obtained
results were scored and sorted on the basis of the binding
energy. The Autodock docking was only done on the
inhibitor ligands that were taken from the crystal struc-
ture to cross check the results of Molecular Operated
Environment [MOE] in terms of binding orientation.
Attempts were also made to evaluate in silico toxicity
and identification of other possible targets for the lead
molecule swertiamarin.
Results
We could design 23 compounds which were docked
into the active site of the crystal structure of HMGR.
The interactions of these molecules were compared with
the presently known inhibitors such as atorvastatin and
simvastatin. Based on the results of docking score a num-
ber of potent ligands for the enzyme HMGR as compared
to swertiamarin were established. It was observed that
the designed molecules SWL18, SWL21, SWL22 showed
better docking score (-60.74; -61.43 and –55.68 respec-
tively) and tight binding in pockets. Docking score of
these molecules were very similar to the atorvastatin and
simvastatin.
Conclusions
SWL18, SWL21, SWL22 possess tight binding with
HMGR as compared to swertiamarin, which suggest that
these molecules could have better HMGR inhibition.
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